BeOne Medicines AG
SWB:49BA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BeOne Medicines AG
SWB:49BA
|
CH |
|
S
|
Sahathai Terminal PCL
SET:PORT
|
TH |
Intrinsic Value
The intrinsic value of 
BeOne Medicines AG (49BA) under the Base Case is 257.6 EUR per share.
Compared with the current market price of 292 EUR, the stock appears
Overvalued by 12% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What BeOne Medicines Does
BeiGene is a cancer drug company that discovers, develops, manufactures, and sells medicines for oncology. Its best-known products are targeted therapies and immunotherapies used to treat different kinds of blood cancers and solid tumors. The company also runs clinical trials to find new drug candidates and expand the uses of its existing medicines.
- Headquarters
- Switzerland CH
- Employees
- 12 000
- IPO date
- Mar 2, 2016
Earnings Waterfall
BeOne Medicines AG
The intrinsic value for BeOne Medicines AG (49BA) under the Base Case is 257.6 EUR.
Compared with the current market price of 292 EUR, the stock appears Overvalued by 12% .